{
    "relation": [
        [
            "",
            "Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV",
            "Group 2: Day 0-H1N1+TIV; Day 21-H1N1",
            "Group 3: Day 0-H1N1; Day 21-H1N1+TIV",
            "Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1"
        ],
        [
            "Description",
            "Participants received 15 mcg H1N1 Vaccine on Day 0; 15 mcg H1N1 Vaccine on Day 21, and Trivalent Influenza Vaccine (TIV) on Day 42",
            "Participants received 15 mcg H1N1 Vaccine + Trivalent Influenza Vaccine (TIV) on Day 0 and 15 mcg H1N1 Vaccine on Day 21",
            "Participants received 15 mcg H1N1 Vaccine on Day 0 and 15 mcg H1N1 Vaccine + Trivalent Influenza Vaccine (TIV) on Day 21",
            "Participants received Trivalent Influenza Vaccine (TIV) on Day 0; 15 mcg H1N1 Vaccine on Day 21, and 15 mcg H1N1 Vaccine on Day 42."
        ]
    ],
    "pageTitle": "Sanofi Pasteur, TIV + H1N1, Pediatric Population - Study Results - ClinicalTrials.gov",
    "title": "",
    "url": "https://clinicaltrials.gov/ct2/show/results/NCT00943202?sect=Xl015&view=results",
    "hasHeader": true,
    "headerPosition": "MIXED",
    "tableType": "RELATION",
    "tableNum": 25,
    "s3Link": "common-crawl/crawl-data/CC-MAIN-2015-32/segments/1438042990900.28/warc/CC-MAIN-20150728002310-00077-ip-10-236-191-2.ec2.internal.warc.gz",
    "recordEndOffset": 851752471,
    "recordOffset": 851739438,
    "tableOrientation": "HORIZONTAL",
    "textBeforeTable": "Reporting Groups No text entered. Significant events and approaches for the overall study following participant enrollment, but prior to group assignment Pre-Assignment Details Participants were healthy males and females, age 6 months to 17 years, recruited from existing volunteer populations and from the communities at large around the clinical sites. Participants were enrolled between 20AUG2009 and 21SEP2009. Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations Recruitment Details \u00a0 Hide Participant Flow \u00a0 Participant Flow Biological: Inactivated H1N1 Vaccine Biological: Trivalent Inactivated Influenza Vaccine Interventions: Influenza Condition: Allocation:\u00a0Randomized; \u00a0 Endpoint\u00a0Classification:\u00a0Safety/Efficacy\u00a0Study; \u00a0 Intervention\u00a0Model:\u00a0Parallel\u00a0Assignment; \u00a0 Masking:\u00a0Open\u00a0Label; \u00a0 Primary\u00a0Purpose:\u00a0Prevention Study Design: Interventional",
    "textAfterTable": "Participant Flow: \u00a0 Overall Study \u00a0 \u00a0 Group 1: Day 0-H1N1; Day 21-H1N1; Day 42-TIV \u00a0 \u00a0 Group 2: Day 0-H1N1+TIV; Day 21-H1N1 \u00a0 \u00a0 Group 3: Day 0-H1N1; Day 21-H1N1+TIV \u00a0 \u00a0 Group 4: Day 0-TIV; Day 21-H1N1; Day 42-H1N1 \u00a0 STARTED \u00a0 \u00a0 133 \u00a0 \u00a0 133 \u00a0 \u00a0 133 \u00a0 \u00a0 132 \u00a0 COMPLETED \u00a0 \u00a0 132 \u00a0 \u00a0 131 \u00a0 \u00a0 133 \u00a0 \u00a0 131 \u00a0 NOT COMPLETED \u00a0 \u00a0 1 \u00a0 \u00a0 2 \u00a0 \u00a0 0 \u00a0 \u00a0 1 \u00a0 \u00a0 Baseline",
    "hasKeyColumn": false,
    "keyColumnIndex": -1,
    "headerRowIndex": 0
}